Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly violating the False Claims Act by directing Medicare beneficiaries to insurers that compensated the company the most, rather than providing unbiased comparisons of insurance plans [2][3]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote failed to disclose that it directed Medicare beneficiaries to plans based on compensation rather than quality [2]. - It is claimed that SelectQuote did not provide unbiased comparison shopping for Medicare Advantage plans and received illegal kickbacks from insurers [2]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [3]. Group 2: Impact on Stock Price - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 4: Company Background - Robbins LLP is a law firm recognized for its work in shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. for allegedly misleading investors regarding the capabilities of its joint venture, HomeSafe Alliance, to fulfill a significant contract with the U.S. Department of Defense [1][2][3]. Group 1: Allegations and Contract Issues - HomeSafe Alliance, a joint venture in which KBR holds a 72% economic interest, was awarded the Global Household Goods Contract by TRANSCOM, which assists U.S. military personnel and their families with relocations [2]. - The complaint alleges that KBR was aware of TRANSCOM's concerns about HomeSafe's ability to meet contract obligations but continued to assert that the partnership was functioning well and would improve in future quarters [3]. Group 2: Stock Price Impact - Following the announcement of issues between TRANSCOM and HomeSafe, KBR's stock price dropped by $3.85 per share (7.29%) to close at $48.93 on June 20, 2025, and fell further by $1.30 (2.65%) to close at $47.63 on June 23, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in leading the class action must submit their papers by November 18, 2025, and can choose to remain absent from the case while still being eligible for recovery [5].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Allegations - The lawsuit claims that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [2]. - The complaint also states that the company was unlikely to meet its previously communicated timeline for submitting the MOLBREEVI BLA, and the delay increased the likelihood of needing additional capital [2]. Stock Price Impact - Following the announcement of a refusal to file (RTF) letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by November 7, 2025, although they can remain absent class members if they choose not to take action [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, which has resulted in significant stock price decline [1][2][3]. Group 1: Allegations and Issues - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - This lack of disclosure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including Briquilimab [2]. - The failure to maintain proper controls also raised the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects for the company [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders of Jasper Therapeutics may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Group 1 - A class action has been filed against KBR, Inc. on behalf of investors who acquired its securities between May 6, 2025, and June 19, 2025 [1] - The allegations center around KBR's joint venture, HomeSafe Alliance, which has a 72% economic interest from KBR and was awarded a contract by the U.S. Department of Defense's TRANSCOM [2] - It is claimed that KBR misled investors about HomeSafe's ability to fulfill the Global Household Goods Contract, despite knowing of TRANSCOM's concerns [3] Group 2 - On June 19, 2025, HomeSafe announced a notice to terminate the Global Household Goods Contract, revealing ongoing issues with TRANSCOM [4] - Following the announcement, KBR's stock price dropped by $3.85 (7.29%) to close at $48.93 on June 20, 2025, and further fell by $1.30 (2.65%) to close at $47.63 on June 23, 2025 [4] - Shareholders interested in leading the class action must submit their papers by November 18, 2025, and can remain absent class members if they choose not to participate [5]

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for allegedly misleading investors regarding its business prospects and financial guidance during a specific period in 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Fluor failed to disclose rising costs associated with major projects due to subcontractor design errors, price increases, and scheduling delays [2]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, significantly impacted Fluor's business and financial results [2]. - Following the release of disappointing financial results for Q2 2025, Fluor revised its financial outlook for FY 2025, projecting adjusted EBITDA of $475 million to $525 million, down from $575 million to $675 million, and adjusted EPS of $1.95 to $2.15, down from $2.25 to $2.75 [3]. Group 2: Stock Price Reaction - After the negative financial disclosures, Fluor's stock price dropped by $15.35 per share, or 27.04%, closing at $41.42 per share on August 1, 2025 [3]. Group 3: Class Action Participation - Shareholders who wish to participate in the class action must submit their papers by November 14, 2025, to serve as lead plaintiff [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of advocating for shareholder rights and holding company executives accountable since 2002 [5].

Group 1 - A class action has been filed against Tronox Holdings PLC (NYSE: TROX) for failing to disclose accurate business prospects during the period from February 12, 2025, to July 25, 2025 [1][2] - The complaint alleges that Tronox misrepresented its revenue outlook and growth potential while downplaying risks associated with seasonality and macroeconomic factors [2] - On July 30, 2025, Tronox reported a significant decline in TiO2 sales, attributing it to a weaker coatings season and increased competition, leading to a 60% reduction in its dividend and a drop in stock price from $5.14 to $3.19, a decline of approximately 38% [3] Group 2 - Shareholders interested in participating in the class action must file their papers by November 3, 2025, to serve as lead plaintiff [4] - Robbins LLP, the firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose a material investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [2][3]. Group 1: Allegations and Investigations - The lawsuit alleges that Semler Scientific did not disclose an investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, concerning the marketing of tests using photoplethysmography technology as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, there was a risk of a civil lawsuit being filed, which led to a stock price drop of $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. Group 2: Settlement and Financial Impact - On April 15, 2025, Semler Scientific reported to the SEC that it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a DOJ lawsuit still exists [4]. - Following the announcement of the settlement, Semler Scientific's stock fell by $3.40 per share, or 9.88%, closing at $31.00 on April 16, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their paperwork by October 28, 2025, to serve as lead plaintiff, representing other class members [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Group 1: Allegations and Company Performance - The complaint alleges that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), specifically that it lacked sufficient details on chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - Following the announcement of a refusal to file (RTF) letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [3]. Group 2: Legal Proceedings and Participation - Shareholders may be eligible to participate in the class action against Savara Inc., with the option to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for allegedly failing to disclose critical information regarding its business prospects, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic challenges and maintain financial flexibility for dividends, while understating the negative impacts of competitive pressures, declining global sales, and product oversupply [2]. - On June 23, 2025, BMO downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, resulting in a 3.21% drop in stock price to $26.87 [3]. - Dow reported disappointing Q2 2025 results on July 24, 2025, with a non-GAAP loss per share of $0.42, significantly worse than the expected loss of $0.17 to $0.18, and net sales of $10.1 billion, a 7.3% year-over-year decline, missing estimates by $130 million. The company also announced a 50% cut in its dividend, causing a 17.45% drop in stock price to $25.07 [4]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Dow Inc. and can contact Robbins LLP if they wish to serve as lead plaintiff, representing other class members [5]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [5].